Date:- 23 May, 2016
Tag:- IMMUNOSCORE® in Colon Cancer

  • Dr. Jérôme Galon to present results of the Immunoscore® worldwide SITC(1) study during the Gastrointestinal Cancer Oral Session

HalioDx SAS, a diagnostic company in immuno-oncology, today announced that key results on Immunoscore® in colon cancer will be presented at the ASCO 2016 annual meeting by Dr Jérôme Galon, Research Director at Inserm, Head of the laboratory of Integrative Cancer Immunology, Paris, France and principal investigator of the study. The presentation entitled “Validation of the Immunoscore® as a prognostic marker in stage I/II/III colon cancer” will focus on the results of a study conducted on thousands of patients by the Immunoscore® worldwide consortium, led by the Society for Immunotherapy of Cancer (SITC).

“Colon cancers, especially stages II and III, are still a challenge that neither conventional prognostic factors nor available biomarkers or expression signatures have managed to overcome. The changing paradigm of evaluating the immune contexture of the tumor instead of focusing solely on tumor cells is a powerful approach, the Immunoscore® Colon assay being the first tangible application of this revolution with the hope for better clinically actionable information for the benefit of patients.” comments Vincent Fert, co-founder and CEO of HalioDx. He adds: “The Immunoscore® worldwide consortium is the largest study ever undertaken to validate a biomarker. The overall performance of Immunoscore® as recorded in initial studies(2) suggests that the assay could be a key adjunct to the AJCC/UICC-TNM classification. HalioDx is very excited by the results to be presented by Dr Jérôme Galon at ASCO 2016 as they involved a significant number of patients worldwide and numerous laboratories sites.”

Oral Abstract Session: Gastrointestinal (Colorectal) Cancer, Sunday Jun 05, 2016 8:00 AM – 11:00 AM

Abstract 3500 – 8:00 AM – 8:12 AM

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

Presenter: Jerome Galon, PhD – Inserm

See abstract:

(1) Society for Immunotherapy of Cancer
(2) Galon J et al. Science 2006, Pagès F et al. JCO 2009, Mlecnik B et al. JCO 2011



Related Files